Tuesday, 04.02.2020 – Why Companies Abandon The Development of New Antibiotics

Links of the day: Biopharma has abandoned antibiotic development. Here’s why we did, too.

Recently, I wrote a piece arguing that pharma companies should be paid directly by the state for developing new drugs (really, they should). This article provides a more in-depth view into why so many pharma companies have abandoned developing antibiotics. Spoiler: It is currently almost impossible to make a profit of it.

Leave a Reply

Your email address will not be published.